Equities Analysts Offer Predictions for UNCY Q3 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Research analysts at Brookline Capital Management raised their Q3 2025 earnings estimates for shares of Unicycive Therapeutics in a research report issued on Tuesday, June 10th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics' Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.15) EPS, FY2026 earnings at ($0.08) EPS, FY2027 earnings at $0.63 EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $1.01 EPS.

A number of other equities analysts also recently weighed in on the stock. Guggenheim began coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They issued a "buy" rating and a $6.00 price target on the stock. HC Wainwright raised shares of Unicycive Therapeutics to a "strong-buy" rating and set a $9.00 price target on the stock in a research note on Tuesday, May 27th.

Unicycive Therapeutics Trading Up 6.8%

NASDAQ:UNCY traded up $0.04 during trading hours on Thursday, hitting $0.68. 4,321,453 shares of the stock traded hands, compared to its average volume of 1,962,427. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.10. The firm has a market cap of $82.20 million, a price-to-earnings ratio of -0.70 and a beta of 2.01. The firm has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.63.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.09.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds have recently bought and sold shares of the company. Northern Trust Corp lifted its stake in shares of Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after buying an additional 34,183 shares during the period. XTX Topco Ltd raised its stake in shares of Unicycive Therapeutics by 142.2% in the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock valued at $136,000 after acquiring an additional 100,679 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after acquiring an additional 122,089 shares during the last quarter. Acuta Capital Partners LLC increased its holdings in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after purchasing an additional 323,801 shares in the last quarter. Finally, Vivo Capital LLC raised its position in Unicycive Therapeutics by 123.0% in the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock worth $7,918,000 after purchasing an additional 5,500,000 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.